In this issue of Blood, Rego and colleagues describe the exciting accomplishments of the International Consortium on Acute Promyelocytic Leukemia (IC-APL), an initiative of the International Members Committee of the American Society of Hematology (ASH).(1) The purpose of this initiative is to create a network of institutions in developing countries that will work in partnership with cooperative groups in the United States and Europe in order to close the gap in quality of care and outcomes in acute promyelocytic leukemia (APL) between developed and developing countries.